Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin

Stopped early · Phase 4

Conditions studied: Infection

In brief

Evaluate the safety and outcomes associated between the two treatment modalities

Key facts

Study ID

NCT04648696

Run by

Wake Forest University Health Sciences

People needed

8

Starts

2021-03-03

Expected to finish

2022-10-31

Last updated by the study team

2024-02-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients at least 18 years of age
• Receiving Wake Forest Baptist Health Outpatient parenteral antimicrobial therapy (OPAT) services
• Will receive vancomycin therapy from Wake Forest Baptist Health Specialty Home Infusion Pharmacy
• Planned therapy with vancomycin in the outpatient setting for at least 2 weeks in duration
• Prescribed vancomycin with a frequency of either every 12 hours or every 8 hours dosing at the time of enrollment

You may not qualify if…

• Presence of diseases or conditions known to affect the pharmacokinetics of vancomycin: Pregnancy/Ascites/Burn injury/Cystic fibrosis /Weight greater-than or equal-to 150 kg
• Pre-existing leukopenia: White Blood Cell (WBC) < 4,000 x 103 cells/µL

Where it is running

• Wake Forest Health Sciences — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.